Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Appropriations for DSHEA

This article was originally published in The Tan Sheet

Executive Summary

Rep. Dan Burton, R-Ind., reintroduced legislation June 14 to ensure the goals of the Dietary Supplement Health and Education Act are met by "authorizing appropriations to fully enforce and implement" the act. Burton co-sponsored the legislation with Rep. Frank Pallone, D-N.J. last session (1"The Tan Sheet" May 30, 2005, p. 14). In the 108th Congress, Pallone introduced similar legislation (2"The Tan Sheet" July 5, 2004, p. 14). The current bill, H.R. 2718, was referred to the House Energy and Commerce Committee...

You may also be interested in...

House Bills Aim To Loosen Health Claims Regs, Fully Fund DSHEA

A new House bill is designed to add flexibility to FDA's health claims oversight, allowing supplement manufacturers to make scientifically accurate disease claims

Rep. Pallone Introduces DSHEA Implementation Companion Bill

The "Dietary Supplement Regulatory Implementation Act of 2004" would establish a system detailing "requirements" for reporting serious adverse events associated with supplement use

More GMP Warnings, Import Alerts For OTC Firms As US FDA Capped List Of Uninspected Facilities

Most of the foreign OTC drug firms targeted in latest warnings FDA published, including the GUM oral care brand manufacturer, were placed on import alert due to GMP violations. Each was inspected by FDA during June, July or May 2019, when the agency was wrapping up an initiative to inspect all previously uninspected drug manufacturers.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts